We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Sensitivity ELISA Diagnoses Wegener's Granulomatosis

By Biotechdaily staff writers
Posted on 02 Oct 2007
Wegener's granulomatosis can now be diagnosed using a high sensitivity (hs) enzyme-linked immunosorbant assay (ELISA).

A fatal disease of unknown etiology, Wegener's granulomatosis is characterized by granuloma in the inflamed tissues of the respiratory tract, systemic vasculitis of small blood vessels, and glomerulonephritis. More...
Anti-neutrophil cytoplasmatic antibodies (ANCA) against cytoplasmic components of neutrophil granulocytes are diagnostic markers for the disease.

Antibodies against proteinase 3 (PR3) distinguish Wegener's granulomatosis from other ANCA-associated small vessel vasculitides such as microscopic polyangiitis and Churg-Strauss syndrome. Currently, diagnosis combines indirect immunofluorescence with an antigen-specific ELISA.

A study of patients with Wegener's granulomatosis--confirmed by clinical data and biopsy results--showed that the Anti-PR3 hs ELISA had a sensitivity of 96% and specificity of 99%. The ELISA is produced by Orgentec Diagnostika (Mainz, Germany) and the results correlated perfectly with indirect immunofluorescence but were superior to immunoblot, direct, and capture ELISA.

Although sera of patients with confirmed Wegener's granulomatosis had negative results for proteinase 3 autoantibodies when tested by the conventional direct ELISA, this assay detected PR3 antibodies in 71% of these sera.

Anti-PR3 hs ELISA detects patients with localized Wegener's granulomatosis corresponding to an early stage of the disease. Due to its sensitivity, high specificity, and excellent correlation with the immunofluorescence test (IFT), the assay replaces the need for complex analysis and significantly simplifies diagnosis of ANCA.

Orgentec Diagnostika develops, produces, and distributes tests for autoimmune diagnostics. Among these tests are methods for diagnosis and therapy monitoring of rheumatic diseases, vasculitis, diabetes and autoimmune disorders of the gastrointestinal tract.


Related Links:
Orgentec Diagnostica

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Thyroid Test
Anti-Thyroid EIA Test
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.